



IBUTAMOREN MESYLATE (MK-677)

Ibutamoren Mesylate (MK-677) is classified as a non-peptide growth hormone secretagogue and mimics the growth hormone stimulating action of ghrelin (a Growth Hormone Releasing peptide found in the GI tract).

Ibutamoren is considered to be potent, long-acting, and is available through oral administration. Clinically, it has been demonstrated to increase the endogenous release of human growth hormone (HGH) as well as insulin-like growth factor-1 (IGF-1) without the adverse increase of prolactin or cortisol often seen with Growth Hormone Releasing Peptides (GHRPs).

Ibutamoren leads to increases in lean body mass, decreases in fat mass and improvements in cholesterol profiles, specifically LDL levels.

Studies have shown Ibutamoren stimulates brain regions involved with metabolic action, such as the hypothalamus and the pituitary.

Ibutamoren may also be effective in increasing both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty and osteoporosis.

Biochemically, Ibutamoren is a long-active orally bioactive agonist of the GHS-R1a. As such, it binds to the same receptor that GHRP2, GHRP6, and Ipamorelin also stimulate.

In order to reduce the negative effect of somatostatin, MK-677 is best taken on an empty stomach with no insulin in the system.

